Compare · GBIO vs GRTS
GBIO vs GRTS
Side-by-side comparison of Generation Bio Co. (GBIO) and Gritstone bio Inc. (GRTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. GBIO focuses on Biotechnology: Pharmaceutical Preparations, while GRTS focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- GBIO is the larger of the two at $347.7M, about the same size as GRTS ($336.5M).
- Both have 8 recent analyst ratings on file.
- Company
- Generation Bio Co.
- Gritstone bio Inc.
- Price
- $5.37-6.20%
- $0.03-30.72%
- Market cap
- $347.7M
- $336.5M
- 1M return
- -1.10%
- -
- 1Y return
- +26.35%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2018
- News (4w)
- 0
- 0
- Recent ratings
- 8
- 8
Generation Bio Co.
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Gritstone bio Inc.
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was founded in 2015 and is headquartered in Emeryville, California.
Latest GBIO
- SEC Form 15-12G filed by Generation Bio Co.
- Amendment: SEC Form SCHEDULE 13G/A filed by Generation Bio Co.
- Amendment: SEC Form SCHEDULE 13G/A filed by Generation Bio Co.
- SEC Form EFFECT filed by Generation Bio Co.
- SEC Form 4 filed by Large owner Atlas Venture Fund X, L.P.
- Director Stehman-Breen Catherine closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Rhodes Jason P
- Director Rowland Charles A Jr closing all direct ownership in the company (SEC Form 4)
- Director Quinn Anthony G. closing all direct ownership in the company (SEC Form 4)
- Director Nicholson Donald William closing all direct ownership in the company (SEC Form 4)
Latest GRTS
- Amendment: SEC Form SC 13G/A filed by Gritstone bio Inc.
- Gritstone bio Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities
- Gritstone bio Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Regulation FD Disclosure
- Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure
- SEC Form SC 13G filed by Gritstone bio Inc.
- Gritstone bio downgraded by JMP Securities
- SEC Form 8-K filed by Gritstone bio Inc.
- Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer
- SEC Form 10-Q filed by Gritstone bio Inc.
- Gritstone bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits